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Abstract: Since their development over 60 years ago, antimicrobials have become an 
integral part of healthcare practice worldwide. Recently, this has been put in jeopardy by 
the emergence of widespread antimicrobial resistance, which is one of the major problems 
facing modern medicine. In the past, the development of new antimicrobials kept us one 
step ahead of the problem of resistance, but only three new classes of antimicrobials have 
reached the market in the last thirty years. A time is therefore approaching when we may 
not have effective treatment against bacterial infections, particularly for those that are 
caused by Gram-negative organisms. An important strategy to reduce the development of 
antimicrobial resistance is to use antimicrobials more appropriately, in ways that will 
prevent resistance. This involves a consideration of the pharmacokinetic and 
pharmacodynamics properties of antimicrobials, the possible use of combinations, and 
more appropriate choice of antimicrobials, which may include rapid diagnostic testing and 
antimicrobial cycling. Examples given in this review include Mycobacterium tuberculosis, 
Gram-negative and Gram-positive organisms. We shall summarise the current evidence for 
these strategies and outline areas for future development. 
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1. Introduction: The Problem of Antimicrobial Resistance 
The theme of World Health Day 2011 “antimicrobial resistance: no action today, no cure 
tomorrow” highlighted antimicrobial resistance as a major issue. Boucher et al. describe the pathogens 
currently presenting the biggest problem in terms of antimicrobial resistance as the ESKAPE 
pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumanii, Pseudomonas aeruginosa, and Enterobacter species [1,2]. The detection of the Metallo-
beta-lactamase (NDM-1) enzyme in 2008 alarmed the international community [3,4]. There is a lack of 
treatment options to deal with some of the multidrug resistant pathogens. The result is the use of (i) 
last-line therapies such as carbapenems, that would ideally be preserved [5]; and (ii) antimicrobials 
previously discarded due to toxicity, such as polymyxins, which have been brought back into use 
despite nephrotoxicity and neurotoxicity [6]. 
The development of novel antimicrobials is a subject of considerable interest, which has been 
discussed in depth by commentators [7–12]. However, new drug development alone cannot solve the 
problem. With few new classes of antimicrobials currently in the pipeline, and others that are still 
years away from the market, resistance prevention strategies have a crucial role to play in preserving 
the lifespan of existing antimicrobials [13,14].  
 Strategies to extend the lifespan of the antimicrobials by preventing antimicrobial resistance 
include: (i) reducing usage of antimicrobials; (ii) appropriate use of antimicrobials; and (iii) infection 
control [15]. According to the World Health Organisation, limiting the development of antimicrobial 
resistance ultimately lies with reducing antimicrobial usage [16]. Reducing antimicrobial usage 
requires tackling a number of difficult areas, including reducing over-the counter purchases, public 
health campaigns, education of medical professionals, and reducing antimicrobial usage in animals, as 
has been discussed by excellent reviews on the subject [5,17–21]. Preventing cross-infection with 
resistant bacteria prevents the spread of antimicrobial resistant infections and so infection control is an 
important strategy, including outbreak control, hand hygiene, barrier precautions, and prophylactic 
antimicrobials, as discussed by reviews [13,16,22,23]. This review will focus on the second core 
strategy, to extend the lifespan of current antimicrobials by using the ones we have in ways that will 
reduce the emergence of resistance.  
2. Appropriate Antimicrobial Usage 
Clinically relevant resistance due to chromosomal mutations develops gradually due to the 
accumulation of alterations [24]. The mutation rate differs between antimicrobial-bacteria pairings 
because some antimicrobials select resistant mutations in certain bacteria more readily. Choice of 
antimicrobial-bacterial pairing, antimicrobial combinations, and appropriate dosing can potentially reduce 
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the emergence of de novo resistance. A good example of this is treatment of Mycobacterium tuberculosis, 
in which resistance arises solely by chromosomal mutations (the successful use of combination therapy 
to avoid resistant mutants for Mycobacterium tuberculosis is discussed in section 2.2.). In contrast, the 
transfer of resistance genes, for instance via plasmids, can confer clinically relevant resistance in a 
single step. Slowing the progress of this type of resistance is extremely difficult [24]. This type of 
resistance transfer is particularly common in multi-species populations in the large intestine in humans. 
Horizontal gene-transfer accounts for much of resistance to antimicrobials in hospital-acquired 
infections for the majority of antimicrobial classes [25]. 
2.1. Pharmacokinetics and Pharmacodynamics 
Pharmacokinetics and pharmacodynamics are topics of great importance in the areas of anti-
bacterial efficacy and clinical outcomes [26]; recently they have also been applied to the topic of 
antimicrobial resistance. 
2.1.1. Dosage 
Progress in the understanding of how the dose of antimicrobials affects resistance has been reviewed 
by Olofsson et al [27]. They describe how single high doses might be better at preventing resistance 
than multiple low doses (as shown in both in vitro and in vivo models [28–34]). Further research is 
required to highlight the optimal doses, which will successfully treat bacterial infections while 
preventing resistance.  
Consensus has not yet been reached regarding which parameter of dose assessment should be used 
in resistance studies. Minimum inhibitory concentration (MIC) is the minimum concentration of an 
antimicrobial that will inhibit the growth of bacteria after an appropriate period of incubation [26]. 
Blaser et al. have showed that maximising the ratio of maximum concentration in serum (Cmax) to MIC 
restricted the growth of resistant mutants in in vitro studies [28]. Moreover, Thomas et al. have 
suggested that selection of antimicrobial resistance is decreased if the ratio of the area under the curve 
(AUC) to MIC is greater than 100 [35]. Traditionally, the efficacy of anti-tuberculosis antimicrobials 
has been associated with a high AUC to MIC ratio. However, in contrast, it has recently been shown 
that in the case of Mycobacterium tuberculosis treatment, the efficacy of isoniazid and rifamycins may 
be determined by peak drug concentrations [36]. More research in this area is needed but, if this 
concept is confirmed, then high doses of rifamycins may be able to shorten tuberculosis treatment. It is 
anticipated that shortening the duration of tuberculosis chemotherapy should lead to an increase in 
patient adherence [37,38].  
Blondeau et al. examined the effect of using high dose fluroquinolones against Streptococcus 
pneumoniae in vitro studies [39]. They used concentrations of fluroquinolones equal to the mutation 
prevention concentration (MPC), concentration above which no first step resistant mutants grow, in 
order to slow the development of fluroquinolone resistance. In vivo studies in rabbits show that the use 
of a levofloxacin concentration greater than MPC supresses the growth of mutant populations in 
Staphylococcus aureus, and use of a vancomycin concentration above MPC or with a high AUC to 
MIC ratio reduces the acquisition of resistance in methicillin-resistant Staphylococcus aureus [40,41]. 
Whether dosing to achieve the MPC will prevent resistance development in human patients needs 
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more investigation. Since each antimicrobial-bacterial pairing has a unique MPC, it may not always be 
possible to achieve the MPC with a safe antimicrobial dose [42]. Recent clinical trial data with 
linezolid show efficacy in extensively drug-resistant tuberculosis, however 82% of patients 
experienced clinically significant adverse events [43]. Although it is bacteriostatic in vitro, it reaches 
high concentrations in the lungs, which somewhat blurs bacteriostatic/bactericidal relevance in vivo. 
This also alludes to the potential role of MPC in reducing resistance. More research is needed to 
ascertain which parameter and levels of dose are optimal to prevent antimicrobial resistance [44,45].  
Mathematical models are being used to examine the theoretical basis for shorter treatment courses and 
optimise the duration and dosing of antimicrobials, which will minimise the duration of symptomatic 
infection as well as the selection pressure for resistance. Recent conclusions from these studies are that 
long durations of antimicrobial therapy are less appropriate for self-limiting infections and that the 
potential for selection for resistance in commensal flora should be taken into account when choosing 
the duration of therapy [46]. 
2.1.2. Distribution and Excretion 
The site of infection and infecting bacteria are not the only considerations for resistance 
development. Normal human microbiota act as a barrier against colonisation by potentially pathogenic 
microorganisms or overgrowth of present organisms: this is known as “colonisation resistance”. 
Antimicrobials can detrimentally affect this microbiota, first by causing resistance, which can then be 
transferred by resistance genes to other microorganisms, and secondly by damaging colonisation 
resistance and allowing colonisation by pathogenic microorganisms or overgrowth of present 
microorganisms, which may be resistant. The degree of disturbance an antimicrobial may cause to 
microbiota depends on its spectrum, route of administration, degree of absorption, route of elimination, 
and inactivation either enzymatically or by binding. Using antimicrobials that cause minimal 
disturbance to the normal human microbiota reduces the risk of emergence and spread of resistance 
strains between patients and the transfer of resistance genes between microorganisms [47].  
Antimicrobials are distributed throughout the body and are present in different tissues (respiratory 
tract, urinary tract, digestive tract) at differing concentrations. It is difficult to measure the concentrations 
of drugs at different sites simultaneously so in vitro models have tried to estimate this [48–50]. Animal 
models are also used to look at tissue distribution in major organs (lungs, spleen, kidneys, intestines, etc.) 
and data often correlates to explain efficacy at site of infection or guide the selection of formulations to 
improve drug disposition. The microbiota present in these sites are an important source of resistance 
development, especially as the bacteria in these locations are usually present in large numbers and the 
antimicrobials may be low in concentration. Low concentrations of antimicrobials are often associated 
with the development of resistance [33,51,52]. 
Oh et al. investigated the effect of the administration of clindafloxacin (a broad-spectrum 
quinolone) on intestinal microbiota in 12 human volunteers, who could be considered to be antibiotic 
naïve [53]. Oral administration resulted in high antimicrobial levels in the faeces of patients, and there 
was significant emergence of clindafloxacin resistant Gram-negative bacilli. As a result of their 
findings, Oh et al. suggested the restricted use of clindafloxacin. A comparison of resistance development 
to antimicrobials that are mainly excreted in bile, such as clindafloxacin, with those which are mainly 
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renally excreted, such as amoxicillin, has been made and it has been suggested that there is more 
resistance development against those which are excreted in bile due to the affect on the microbiota in 
the large bowel [54]. This is an important area for future research that could inform future drug 
development and use of current antimicrobials. Rashid et al. compiled data on the ecological impact of 
new antimicrobial agents (ceftobiprole, ceftarolone, telavancin, dalbavancin, and tigecyclin) on the 
gastrointestinal microbiota of healthy volunteers and found them to have only minor ecological  
effects [47]. Ertapenem is primarily renally excreted and was expected to have a small affect on gut 
microbiota. However, a study of 10 healthy volunteers where ceftriaxone and ertapenem were 
administered intravenously once daily at dosages 1 g and 2 g respectively found considerable 
ertapenem in faeces and its impact on gut microbiota was similar to that of ceftriaxone [55]. A clinical 
trial of adults with complicated intra-abdominal infections, treated with piperacillin-tazobactam (3.375 g 
every 6 hours), or ertapenem (1 g once a day) for 4 to 14 days, were compared for bowel colonisation 
with resistant bacteria. Lower acquisition of resistant Enterobacteriaceae was found with ertrapenem [56]. 
Orally administered sustained-release formulations can be used to reduce the frequency of dosing 
required for antimicrobials with relatively short half-lives [57]. Orally administered antimicrobials are 
predominantly excreted in bile and sustained-release formulations result in an even higher level of 
drug in the colon and a greater potential for resistance to develop. The effect of orally administered 
sustained-release delivery systems on the development of resistance in the microbiota of rats has been 
studied and it was found that oral sustained-release amoxicillin resulted in more resistance [58]. 
Goldstein reviewed the effects of antimicrobials on gut microbiota in the hospital environment [59]. 
As opposed to the healthy volunteers in the studies conducted by Oh et al., the patients discussed here 
could be considered to be antibiotic non-naïve. Clostridium difficle infection was highlighted as a 
growing problem in hospitals worldwide, particularly due to the disruption of gut microbiota that 
occurs with the use of broad-spectrum antimicrobials. Infection control measures and antimicrobial 
stewardship were outlined as two important strategies for Clostridium difficle infection prevention. 
Another important example discussed was the risk of intestinal colonization with resistant bacteria in 
patients receiving antimicrobials for intra-abdominal infections. Optimizing Intra-Abdominal Surgery 
with Invanz studies (OASIS-I and OASIS-II) suggest that resistant Enterobacteriaceae is less like to 
develop in patients treated with ertapenem compared to piperacillin/tazobactam. Furthermore, recent 
studies suggest the increased use of non-pseudomonal carbapenems (for example, ertapenem) does not 
decrease the susceptibility of Pseudomonas aeruginosa to the pseudomonal carbapenems (such as 
imipenem and meropenem). Indeed, increased ertapenem and decreased imipenem use in one study 
showed increased susceptibility of Pseudomonas aeruginosa to imipenem.  
Examples of resistance gene transfer during therapy involving microbiota organisms have been 
identified. They include the isolation of Klebsiella pneumoniae carbapenemase (KPC) 3–producing 
Escherichia coli from a carrier of KPC-3–producing Klebsiella pneumonia, where the patient's gut 
flora contained a carbapenem-susceptible Escherichia coli strain isogenic with the KPC-3–producing 
isolate, suggesting horizontal interspecies plasmid transfer [60]. Also the isolation of Staphylococcus 
epidermis and methicillin-resistant Staphylococcus aureus, both expressing a plasmid expressing 
resistance gene mupA, suggests a transfer of resistance gene mupA from Staphylococcus epidermis to 
methicillin-resistant Staphylococcus aureus during a trial of mupirocin for nasal decolonization [61]. 
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A greater understanding of microbiota in the body is required to understand the true impact of 
antimicrobials on microbiota and the generation of resistance. Much is known about the oral 
microbiota, with around 700 species identified [62]. However, only 50% of the organisms are 
culturable so techniques such as pyro-sequencing analysis are being used to study the oral microbiota 
in more detail [63]. Culture-independent techniques have also enhanced the understanding of 
microbiotal communities in the colon [64]. Knowledge about skin microbiota is currently mostly from 
culture based studies with only a few culture-independent studies reported [65,66]. Culture-independent 
approaches have an important role to play in the understanding of human microbiota, which is 
necessary to increase our understanding of the development of resistance there. 
2.2. Combination Therapy 
The use of combination therapy is common in clinical practice for a number of reasons. First, 
preventing antimicrobial resistance. The regimen for which the use of combination therapy to prevent 
bacterial resistance is best established is the treatment of Mycobacterium tuberculosis. The British 
Medical Research Council, led by Denis Mitchison and Wallace Fox, pioneered multi-drug regimens 
for tuberculosis using the first randomised clinical trials [67,68]. This concept was extended to 
treatment of leprosy, human immunodeficiency virus, and cancer. Combinations are used in these 
cases because resistance to agents develops relatively easily. Such combinations have been most 
successful, since Mycobacterium tuberculosis develops resistance by chromosomal mutations, rather 
than by plasmid transfer, and since the organism lives on its own in the tissues, and does not rely of the 
transfer of resistance from other bacterial species. Other examples of combinations that are used to 
delay resistance development to the individual components are co-trimoxazole (sulphonamide and 
trimethoprim); lincomycine and spectinomycine; and aminoglycosides and colistin [69]. 
Second, some antimicrobials enhance one another’s anti-bacterial activity: in other words are synergistic. 
An example of such a combination is the use of penicillin and gentamicin for bacterial endocarditis.  
Third, when a critically ill patient is admitted with suspected septicaemia, and the pathogen is 
unknown at that stage, doctors treat with several antimicrobials in order to broaden the spectrum of 
species of bacteria that are targeted [70]. For instance, a combination of a beta-lactam and an 
aminoglycoside may be used. 
Fourth, combinations can specifically target resistant bacteria. For example, the addition of clavulanic 
acid, which is a beta-lactamase inhibitor, to amoxicillin, renders the amoxicillin active against some 
beta-lactamase producing bacteria. For instance, Dagan et al. compared amoxicillin with amoxicillin 
plus clavulanic acid (Augmentin) for the treatment of non-bullous impetigo [71]. Staphylococcus 
aureus was isolated from all patients and it was found that all isolates of Staphylococcus were sensitive 
to Augmentin but resistant to amoxicillin. The clinical response was significantly better in the 
Augmentin recipients. Bacteria produce many different kinds of beta-lactamases and so, potentially, 
this is an on-going approach for the enhancement of old antibiotics. For example, recent in vivo studies 
in mice show efficacy of meropenem/clavulanate and amoxicillin/clavulanate combinations against 
replicating and non-replicating Mycobacterium tuberculosis [72]. 
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Fifth, if dormant bacteria are important in an infection. For example, the addition of anti-dormancy 
agents such as pyrazinamide and rifampicin to combinations for the treatment of tuberculosis has 
shortened the duration of chemotherapy from 18 to 6 months [38]. 
A meta-analysis (including data from eight randomised controlled trials) that compared 
aminoglycoside/beta-lactam combination therapy with beta-lactam mono-therapy to observe the 
emergence of antimicrobial resistance found that aminoglycoside/beta-lactam combination therapy was 
not associated with reduced development of resistance when compared with beta-lactam therapy alone [73]. 
Animal model studies in the 1980s suggested that the addition of an aminoglycoside to beta-lactam 
therapy might prevent the development of resistance, particularly in the treatment of Pseudomonas 
aeruginosa [74,75]. Human trials in patients with cystic fibrosis also showed that Pseudomonas 
aeruginosa resistance occurred less frequently during combination compared to single therapy [76]. 
The high frequency of chromosomal mutations in Pseudomonas spp. was suggested to support the role 
of combination therapy [75]. As well as prevention of resistance, suggested benefits of combination 
therapy for Pseudomonas aeruginosa include antimicrobial synergy and improved adequacy of 
empirical therapy. The benefits of combination therapy must be balanced against the risk of creating 
multi-drug resistance organisms [77]. This may be of particular concern if the effect of agents on 
bacteria, initially not involved in the pathogenesis, results in horizontal gene transfer of resistance 
genes to the pathogens. 
Combination therapy for the treatment of Neisseria gonorrhoeae has recently been suggested as 
potentially reducing the development of antimicrobial resistance but we could find no controlled study 
data on this [78]. Bonhoeffer et al. used a mathematical model to assess whether combination therapy 
might be useful in the treatment of Neisseria gonorrhoeae and concluded that resistance might be 
preventable with more widespread use of combination therapy [79]. 
2.3. Choice of Antimicrobial 
2.3.1. Bacteria-Antimicrobial Pairings 
The rates of spontaneous resistance mutations for bacteria-antimicrobial pairings at certain 
antimicrobial concentrations are known. By considering the bacterial loads in different infected lesions, 
it is possible to estimate whether or not resistance to an antimicrobial is likely to develop. In some 
clinical situations, the probability of resistant variants being selected is so high that certain 
antimicrobials may be best avoided [42]. Bacteria-antimicrobial pairings that are considered high risk 
for the development of resistance due to de novo mutations include rifampicin and all species of 
bacteria; quinolones and Staphylococcus aureus or Pseudomonas aeruginosa; and cephalosporins and 
Enterobacter spp. or Citrobacter spp [26]. In contrast to rifampicin, for example, it has been suggested 
that antimicrobials that target the cell membrane may induce less resistance [80]. Multi-targeting 
versus single-target antimicrobials is another exciting area of investigation [81]. 
2.3.2. Rapid Diagnostic Techniques 
Narrow-spectrum antimicrobials should be used instead of broad-spectrum antimicrobials where 
possible to avoid affecting microbiota. Use of more narrow-spectrum antimicrobials may reduce 
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incidence of Clostridium difficile infection. Culturing bacteria can take days; therefore non-targeted 
broad-spectrum antimicrobials are often used first before sensitivities are known. Rapid diagnostic 
tests have been developed, which can help doctors target bacteria more quickly [5]. Group A beta-
haemolytic streptococcus (GABHS) is the most common bacterial cause of pharyngitis [82]. Throat 
swab culture is the gold standard for diagnosis but results take one to two days. Rapid antigen 
detection testing gives results in 10–15 minutes (specificity greater than or equal to 95%, sensitivity 
greater than or equal to 90%). Madurell et al. showed that the use of rapid antigen detection tests to 
identify GABHS in patients with acute pharyngitis helped doctors identify target bacteria and devise a 
rational treatment approach. Procalcitonin (PCT) can be used as a biomarker for bacterial infections [83]. 
Burkhardt et al. compared PCT-guided antimicrobial treatment to standard care in patients with an acute 
respiratory tract infection. They showed that PCT-guided treatment reduced the antimicrobial treatment 
rate by 41.6% [84]. 
2.3.3. Antibiotic Surveillance and Stewardship 
The choice of antimicrobials is generally based on guidelines, which include knowledge of surveillance 
of bacterial susceptibility, and resistance to antimicrobials in different regions and countries. Targeted 
programs of active surveillance can potentially be used to guide empirical therapy [85]. Different types of 
surveillance used include governmental, institutional, industrial, and pharmaceutical programs, but 
there will inevitably be a time-lag between the results of surveillance systems and decision making in 
clinical contexts [86]. Antibiotic stewardship is coordinated interventions that aim to measure and 
improve antimicrobial usage. This includes the promotion of appropriate selection of antimicrobials, 
dosage, route, and duration of therapy. 
2.3.4. Antimicrobial Cycling 
Antimicrobial cycling is scheduled rotations of antimicrobial usage between drugs with a similar 
spectrum of activity. The principle is that the more often an antimicrobial is prescribed, the more 
resistance will develop against it, and withdrawing antimicrobials for a time will remove the selective 
pressure, allowing resistance rates to stabilize or fall. It is important to note that the restriction of 
sulphonamide use nationally in the UK did correlate with a reduction in the resistance of 
sulphonamide-resistant Escherichia coli [87]. Bennett et al. reported an improvement in the 
antimicrobial susceptibility profile of Gram-negative organisms (Pseudomonas aeruginosa, 
Escherichia coli, and Klebsiella pneumoniae) in a surgical intensive care unit compared to the medical 
intensive unit after the implementation of rotation of piperacillin/tazobactam, imipenem/cilastin, 
ceftazidime, and ciprofloxacin as the primary antibiotic used to treat suspected gram-negative 
infections every month [88]. However, a review of both clinical trials and mathematical modelling 
studies examined the efficacy of antimicrobial cycling to prevent resistance and reported there was not 
evidence to support the implementation of antimicrobial cycling as a strategy for reducing 
antimicrobial resistance in hospitals [89]. 
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3. Conclusions 
Three core strategies to extend the lifespan of our current antimicrobials are: (i) reducing usage of 
antimicrobials; (ii) better use of antimicrobials; and (iii) infection control. This review examines the 
literature relating to the second strategy, to use antimicrobials more appropriately, concentrating on 
three areas: pharmacokinetics/pharmacodynamics, combination therapy, and appropriate choice of 
antimicrobials. 
For mycobacterium tuberculosis the use of multi-drug combination therapy is an established 
strategy being used to prevent resistance to treatment. Furthermore, it has recently been suggested that 
the efficacy of the core anti-tuberculosis drugs, isoniazid and rifamycins, is determined by peak drug 
concentrations. This may mean that tuberculosis regimes can be shortened and, if so, an improvement 
in adherence would hopefully mean a reduction in resistance to treatment.  
For other bacterial infections, strategies to use antimicrobials in a way that will reduce resistance 
development are yet to be clearly established. We hope that the subject areas we have outlined in this 
article can be developed to help us to use our existing antimicrobials in ways that will extend their 
lifespan by preventing antimicrobial resistance. 
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